



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 5/06, 5/08, A61K 38/55, C07K 14/705, G01N 33/68, A01K 67/027</b>		A1	(11) International Publication Number: <b>WO 99/48910</b> (43) International Publication Date: 30 September 1999 (30.09.99)																																													
(21) International Application Number: <b>PCT/GB99/00963</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).																																														
(22) International Filing Date: 26 March 1999 (26.03.99)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>																																														
(30) Priority Data: 9806442.1 26 March 1998 (26.03.98) GB 60/086,966 28 May 1998 (28.05.98) US		(71) Applicant (for all designated States except US): UNIVERSITY OF DUNDEE [GB/GB]; Dundee DD1 4HN (GB).																																														
(72) Inventor; and (75) Inventor/Applicant (for US only): WATTS, Colin [GB/GB]; 15 Westfield Terrace, Newport-on-Tay DD6 8HX (GB).		(74) Agent: MILES, John; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).																																														
		<p><i>This paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10</i></p> <p><i>Mailing Label No. <u>EL 585712904US</u></i></p>																																														
(54) Title: USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE																																																
<p><b>a</b></p> <table border="1"> <tr> <td></td> <td>Iodoacarbamate</td> <td>Leupeptin</td> <td>EE64</td> <td>Pepstatin</td> </tr> <tr> <td>TTCF</td> <td colspan="4"></td> </tr> <tr> <td></td> <td colspan="4">pH 4.5 6.0 7.0</td> </tr> </table> <p><b>b</b></p> <table border="1"> <tr> <th>Fragment</th> <th>Sequence/ cleavage site</th> </tr> <tr> <td>1</td> <td>2,4 RHIDN EEDID</td> </tr> <tr> <td>2</td> <td>5 YTPNN EIDSF</td> </tr> <tr> <td>3</td> <td></td> </tr> <tr> <td>4</td> <td></td> </tr> <tr> <td>5</td> <td></td> </tr> <tr> <td>6</td> <td>6 GNAFN NLDR</td> </tr> </table> <p><b>c</b></p> <table border="1"> <tr> <td colspan="2"></td> <td colspan="2">Lysosome fraction</td> </tr> <tr> <td colspan="2"></td> <td>-</td> <td>+</td> </tr> <tr> <td colspan="2"></td> <td>-</td> <td>+</td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> </tr> </table>					Iodoacarbamate	Leupeptin	EE64	Pepstatin	TTCF						pH 4.5 6.0 7.0				Fragment	Sequence/ cleavage site	1	2,4 RHIDN EEDID	2	5 YTPNN EIDSF	3		4		5		6	6 GNAFN NLDR			Lysosome fraction				-	+			-	+				
	Iodoacarbamate	Leupeptin	EE64	Pepstatin																																												
TTCF																																																
	pH 4.5 6.0 7.0																																															
Fragment	Sequence/ cleavage site																																															
1	2,4 RHIDN EEDID																																															
2	5 YTPNN EIDSF																																															
3																																																
4																																																
5																																																
6	6 GNAFN NLDR																																															
		Lysosome fraction																																														
		-	+																																													
		-	+																																													
<p>(57) Abstract</p> <p>A method of modulating the immune response in a patient in need of such modulation, the method comprising administering to the patient an effective amount of an inhibitor of asparaginyl endopeptidase. A method of reducing the processing of a protein antigen by a MHC Class II molecule by a cell, the method comprising contacting the cell with an inhibitor of asparaginyl endopeptidase.</p>																																																

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		